Precigen Inc (PGEN)

Jan 13, 2025, 7:00 AM EST - 4 days ago

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:30 AM EST - 8 days ago

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 30, 2024, 7:00 AM EST - 18 days ago

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Dec 27, 2024, 9:00 AM EST - 21 days ago

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Nov 14, 2024, 4:30 PM EST - 2 months ago

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Nov 12, 2024, 4:05 PM EST - 2 months ago

Precigen to Participate in the Stifel 2024 Healthcare Conference

Sep 16, 2024, 4:30 PM EDT - 4 months ago

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Aug 15, 2024, 8:11 AM EDT - 5 months ago

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

GGR TITN

Aug 14, 2024, 7:03 PM EDT - 5 months ago

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 5 months ago

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Aug 9, 2024, 8:00 AM EDT - 5 months ago

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Aug 7, 2024, 9:30 PM EDT - 5 months ago

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Aug 6, 2024, 4:04 PM EDT - 5 months ago

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Aug 6, 2024, 4:01 PM EDT - 5 months ago

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Jul 23, 2024, 8:01 AM EDT - 6 months ago

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Jun 3, 2024, 9:30 AM EDT - 8 months ago

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

May 23, 2024, 5:00 PM EDT - 8 months ago

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

May 14, 2024, 4:05 PM EDT - 8 months ago

Precigen Reports First Quarter 2024 Financial Results and Business Updates

May 8, 2024, 4:05 PM EDT - 9 months ago

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

Apr 24, 2024, 10:20 AM EDT - 9 months ago

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Apr 24, 2024, 9:00 AM EDT - 9 months ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB XOMA

Mar 28, 2024, 4:05 PM EDT - 10 months ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Mar 19, 2024, 8:49 PM EDT - 10 months ago

Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 4:05 PM EDT - 10 months ago

Precigen Reports Full Year 2023 Financial Results and Business Updates

Mar 12, 2024, 4:05 PM EDT - 11 months ago

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Mar 5, 2024, 4:05 PM EST - 11 months ago

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

Feb 6, 2024, 4:05 PM EST - 1 year ago

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 19, 2024, 7:39 PM EST - 1 year ago

Precigen: RRP Targeting With AdenoVerse Technology Platform

Jan 16, 2024, 8:05 AM EST - 1 year ago

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Jan 8, 2024, 8:30 AM EST - 1 year ago

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 18, 2023, 4:05 PM EST - 1 year ago

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 29, 2023, 4:05 PM EST - 1 year ago

Precigen to Participate in the JMP Securities Hematology and Oncology Summit

Nov 9, 2023, 4:55 PM EST - 1 year ago

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

Nov 7, 2023, 4:05 PM EST - 1 year ago

Precigen to Participate in the Stifel 2023 Healthcare Conference

Sep 19, 2023, 4:05 PM EDT - 1 year ago

Precigen to Participate in Upcoming Leading Investor and Industry Conferences

Aug 28, 2023, 9:15 AM EDT - 1 year ago

Precigen's Express Lane: Racing Towards RRP Remedies (Rating Upgrade)

Aug 9, 2023, 3:03 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 8:00 AM EDT - 1 year ago

Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025

Aug 9, 2023, 7:05 AM EDT - 1 year ago

Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

Aug 3, 2023, 4:05 PM EDT - 1 year ago

Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th

Jun 20, 2023, 7:30 AM EDT - 1 year ago

Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Jun 5, 2023, 4:05 PM EDT - 1 year ago

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

Jun 3, 2023, 12:00 PM EDT - 1 year ago

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

May 31, 2023, 8:05 AM EDT - 1 year ago

Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

May 10, 2023, 2:59 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q1 2023 Earnings Call Transcript

May 10, 2023, 8:00 AM EDT - 1 year ago

Precigen Reports First Quarter 2023 Financial Results and Business Updates

May 3, 2023, 8:30 AM EDT - 1 year ago

Precigen to Announce First Quarter 2023 Financial Results on May 10th

Apr 26, 2023, 4:05 PM EDT - 1 year ago

Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse™ Immunotherapy at the 2023 ASCO Annual Meeting

Apr 26, 2023, 12:15 AM EDT - 1 year ago

Strong Small-Cap Insider Buys: Q1 2023

AAT ABBV BY CCB CCO CMP ENVX

Apr 17, 2023, 9:01 AM EDT - 1 year ago

Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023